on the implications of c-Kit inhibitors on response rates for unresectable or metastatic MM, acral and sun-damaged melanomas demonstrated that objective responses were almost exclusively achieved by patients harboring KIT mutations in exon 11 and exon 13.97 This evidence concerns the gene KIT and Miyoshi myopathy.